^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TNFRSF8 negative

    i
    Other names: TNFRSF8, TNF Receptor Superfamily Member 8, Tumor Necrosis Factor Receptor Superfamily Member 8, Lymphocyte Activation Antigen CD30, CD30L Receptor, Ki-1 Antigen, D1S166E, CD30, Tumor Necrosis Factor Receptor Superfamily, Member 8, Cytokine Receptor CD30, CD30 Antigen, TNFRSF8, Ki-1
    Entrez ID:
    943
    Related biomarkers:
    Expression
    Others
    1year
    Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. (PubMed, Clin Lymphoma Myeloma Leuk)
    Overall, EPOCH was well tolerated with high response rates in first line and R/R setting.
    Journal • Real-world evidence • Real-world
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 negative
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone
    almost2years
    Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs). (PubMed, Blood)
    These entities are currently treated similarly with CHOP or CHOEP for CD30-negative diseases or brentuximab vedotin plus CHP for CD30-positive diseases, followed by consolidation with autologous stem cell transplant in first remission...Although current treatment strategies lump most disease entities together, future treatment will include distinct strategies for each disease subtype that optimizes therapy for individuals. This movement towards individualized therapy will ultimately lead to dramatic improvements in prognosis for patients with PTCL.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive • TNFRSF8 negative
    |
    Adcetris (brentuximab vedotin)
    almost2years
    Administration of T Lymphocytes for Prevention of Relapse of Lymphomas (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center
    Trial completion date
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression • ALK negative • TNFRSF8 negative
    |
    TT11
    2years
    First Report of Asymptomatic Solitary High-Grade B-Cell Lymphoma NOS: An Enigmatic Entity (ASH 2023)
    Following discussions with Henry Ford Lymphoma Tumor Board, patient was treated with six cycles of R-CHOP, where follow-up imaging indicated remission of her lymphoma. ConclusionThis represents an extraordinary first report of HGBL NOS manifesting as an isolated primary hepatic lymphoma in the complete absence of clinical symptoms. The significance of this case lies in its atypical extra-nodal site of involvement and total absence of clinical symptoms and serological markers, underscoring the unfulfilled need to further describe this enigmatic entity.
    IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6) • MME (Membrane Metalloendopeptidase)
    |
    CD20 positive • BCL2 rearrangement • TNFRSF8 negative
    |
    Rituxan (rituximab)
    2years
    Differential expression of BCL11b and CDKN2A in CD30-positive peripheral T cell lymphoma: Retrospective study. (PubMed, Medicine (Baltimore))
    These results indicate that BCL11b may be involved in CD30 differentiation and PTCL prognosis. The detection and targeting of BCL11b and CD30 may provide new strategies for the treatment and classification of PTCL.
    Retrospective data • Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL11B (BAF Chromatin Remodeling Complex Subunit BCL11B)
    |
    TNFRSF8 positive • TNFRSF8 expression • TNFRSF8 negative • CDKN2A expression
    2years
    Multimodal dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin’s lymphoma (DGHO 2023)
    We provide a framework for unbiased, multi-dimensional target screening and highlight the functional relevance of the immunosuppressive CTLA-4-CD86 axis in HL. Our results further emphasize the role of anti-CD86 - targeted therapies either as an alternative to or in conjunction with anti-CD30-based therapies in HL.
    CAR T-Cell Therapy
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD86 (CD86 Molecule)
    |
    TNFRSF8 expression • TNFRSF8 negative
    over2years
    Spatially Resolved Transcriptomes of CD30+-transformed Mycosis Fungoides and Cutaneous Anaplastic Large-cell Lymphoma. (PubMed, J Invest Dermatol)
    In CD30-negative ROIs in MF-LCT compared to cALCL, memory B (p=0.021), plasma (p=0.023), and CD8 memory T (p=0.001) cells significantly decreased whereas regulatory T cells (p=0.024) increased. Predomination of ECM remodeling pathways and immunosuppressive microenvironment in MF-LCT indicates pathophysiological differences from MF-LCT and cALCL.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive • TNFRSF8 expression • TNFRSF8 negative
    over2years
    Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients (clinicaltrials.gov)
    P2, N=58, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 negative
    |
    Adcetris (brentuximab vedotin)
    over2years
    A new case of lymphomatoid papulosis and mycosis fungoides coexistence (WCD 2023)
    LyP treatment options include topical steroids, topical bexarotene, phototherapy, nitrogen mustard, methotrexate, and intralesional interferon. In our patient, the papules and ulcerated plaques regressed under treatment with methotrexate
    Clinical
    |
    CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • IL2RA (Interleukin 2 receptor, alpha) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    TNFRSF8 expression • CD8 expression • TNFRSF8 negative
    |
    methotrexate • Targretin gel (bexarotene topical) • Valchlor (mechlorethamine gel)